Results 51 to 60 of about 6,286 (187)
International Journal of Cancer, EarlyView.ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang +10 more
wiley +1 more source
PLoS ONE, 2013 Lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung infections are major causes of morbidity and mortality among HIV-infected patients even in the era of antiretroviral therapy (ART).
Sravanthi Gundavarapu +10 more
doaj +1 more source
Journal of Clinical Laboratory Analysis, EarlyView.Thoracic aortic aneurysm (TAA) is a life‐threatening cardiovascular disease with limited therapeutic options. Through single‐cell RNA sequencing of aortic tissues from healthy individuals and TAA patients (105,541 cells), we identified CLEC5A+macrophages as the predominant pathogenic cell population exhibiting the highest M1 polarization score. Machine
Xiangyu Li +3 more
wiley +1 more source
Expression of mammalian GPCRs in
BMC Biology, 2006 Background G-protein-coupled receptors (GPCRs) play a crucial role in many biological processes and represent a major class of drug targets. However, purification of GPCRs for biochemical study is difficult and current methods of studying receptor-ligand
Jansen Gert +6 more
doaj +1 more source
Precision Medical Sciences, EarlyView.Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley +1 more source
Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
Molecules, 2008 CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1 ...
Hualiang Jiang +7 more
doaj
BMC Infectious Diseases, 2019 Background The circumstances of prescription of tropism tests clinically relevant in treatment-experienced patients are unclear. Methods We performed a monocentric retrospective analysis of all tropism tests performed between 2006 and 2015 in HIV ...
Laurène Deconinck +6 more
doaj +1 more source
A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. [PDF]
PLoS ONE, 2011 Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease CCR5 expression and improve natural killer cell function ex vivo.
Pablo Tebas +8 more
doaj +1 more source
Small, EarlyView.A microfluidic model of the glioblastoma (GBM) margin was developed to mimic patient‐specific blood‐brain tumor barrier (BBTB) function and drug response. The platform revealed inter‐patient variability in barrier integrity and drug sensitivity, offering a tool for personalized therapy evaluation in GBM.
Minsu Ryoo +16 more
wiley +1 more source
Maraviroc: a review of its use in HIV infection and beyond
Drug Design, Development and Therapy, 2015 Shawna M Woollard, Georgette D Kanmogne Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA Abstract: The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope ...
Woollard SM, Kanmogne GD
doaj